while at the moment breast cancer patients the two anti-HER2 drugs separately receive Herceptin as a subcutaneous injection and Perjeta as an intravenous infusion, says the CHMP. According to the ...

The Perjeta-based regimen should be administered ... This delivers Herceptin to patients in two-to-five minutes via injection, compared to 30-to-90 minutes via IV.

an investigational biosimilar of Perjeta ® (pertuzumab). Pertuzumab has been approved in various countries and regions in combination with trastuzumab and chemotherapy for the neoadjuvant ...